Antibiotic Exposure During the First 6 Months of Life and Weight Gain During Childhood

Jeffrey S Gerber1, Matthew Bryan2, Rachael K Ross3

  • 1Center for Pediatric Clinical Effectiveness, Division of Infectious Diseases, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

JAMA
|March 23, 2016
PubMed

Insights

Early antibiotic exposure in infants was not linked to significant weight gain by age 7. Limiting antibiotic use in healthy children is advised for other reasons, not weight concerns.

Area of Science:

  • Pediatric Health
  • Microbiome Research
  • Public Health

Background:

  • Early-life antibiotic exposure is common and linked to adiposity in animal models via the gut microbiome.
  • Human infant studies show inconsistent results regarding antibiotic use and childhood weight gain.

Purpose of the Study:

  • To investigate the association between early-life antibiotic exposure and childhood weight gain.

Main Methods:

  • Retrospective, longitudinal study of over 38,000 singleton births and 92 twins.
  • Systemic antibiotic use in the first 6 months of life was the exposure.
  • Weight was measured from 6 months through 7 years.

Main Results:

  • No significant association was found between antibiotic exposure in the first 6 months and weight change rate in singletons (P=.07).
  • Among twins, antibiotic exposure also showed no significant association with weight difference (P=.30).

Conclusions:

  • Early-life antibiotic exposure (first 6 months) is not statistically associated with significant weight gain through age 7.
  • While other reasons exist to limit antibiotic use in young children, weight gain is not a primary concern.
Abstract

Related Concept Videos

Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
10
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
11
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.1K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
720
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
678